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Michel de Lorgeril* and Patricia SalenAbstract
Background: Physical exercise and healthy dietary habits are recommended to prevent breast cancer.
Discussion: Increased intake of omega-3 fatty acids associated with decreased omega-6 - resulting in higher
omega-3 to omega-6 ratio compared with Western-type diet - is inversely associated with breast cancer risk. The
modernized Mediterranean diet with high omega-3 to omega-6 ratio, high fiber and polyphenol intake, and
consumption of low-glycemic index foods reduces overall cancer risk and specifically breast cancer risk. It has been
suggested that consuming no more than one alcoholic drink per day, preferably wine, is preferable. Eliminating
environmental contaminants, including endocrine disruptors, and favoring organic foods to increase polyphenol
intake and the omega-3 to omega-6 ratios were also shown to be beneficial. Cholesterol-lowering statins may
decrease antitumor defenses; are toxic for the mitochondria; decrease the omega-3 to omega-6 ratio; increase body
mass index, insulin resistance and diabetic risk; and have been associated with an increased breast cancer risk.
Summary: Therefore, as well as making lifestyle changes to decrease breast cancer risk, we argue that physicians
should carefully consider (and often avoid) therapies that may increase breast cancer or diabetes risk in high-risk
women and women who wish to decrease their breast cancer risk.
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Breast cancer (BC) remains a leading cause of death
from cancer and a scientific challenge for the medical
community [1]. One critical issue is how to implement
an effective preventive strategy [2]. Risk factors such as
genetic predisposition cannot be modified whereas other
factors (unhealthy diet, sedentary lifestyle) can be avoided
[3]. Other strategies - for instance, decreasing the length of
time a woman’s breast tissue is exposed to estrogens - may
help prevent BC but have proved difficult to implement [4].
Increasing protective factors is critical, in particular
among high-risk women [3]. The effects of dietary fac-
tors have been examined. For instance, dietary fats have
been extensively studied in the prevention of BC [5-7] but
only marine omega-3 fatty acids (n-3) may be protective
[5]. In a meta-analysis of 21 independent prospective
cohort studies, a significant reduction of BC risk with
marine n-3 was found [8]. By contrast, omega-6 fatty
acids (n-6) may increase BC risk [9,10]. Although not all* Correspondence: michel.delorgeril@ujf-grenoble.fr
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2014studies [9] show a link between n-6 and increased BC risk,
the most recent and well-conducted studies actually indi-
cate a positive association between n-6 and BC risk [10].
The pro-cancer effect of n-6 has also been suggested in
randomized controlled trials in which n-6 intakes were
modified [11,12]. These trials were not specifically refer-
ring to BC but to cancers in general, in particular because
the numbers of cancers were too small to analyze specific
cancers. However, in the same way as smoking increases the
risk of lung, bladder and BC, the data suggest that n-6 may
increase the risk of several cancers. If n-6 increase cancer
risk in general, it is reasonable to think that they may also
increase BC risk as epidemiological studies did suggest [10].
As both n-3 and n-6 may contribute to BC risk indi-
vidually (but in opposite directions), they may introduce
confusion in their respective analyses. Thus, when ana-
lyzing the associations between n-3 and BC risk, it is
critical that n-6 is included in the analyses. This is what
Yang et al. did in their recent study [13]. They used the
ratio of n-3 to n-6 in a meta-analysis including 274,135
women from 11 independent prospective studies and
found that women with a higher n-3/n-6 ratio had aCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly cited.
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low n-3/n-6 ratio [13].
Thus, all the factors influencing the n-3/n-6 ratio are crit-
ical in BC risk [14]. Increased intake of n-3 and decreased
intake of n-6 through consumption of foods rich in n-3 and
poor in n-6 [10,15] - resulting in higher n-3/n-6 ratio - is
therefore important to decrease BC risk [13,14]. Polyphenol
flavonoids that increase marine n-3 by about 30% - possibly
through the stimulation of endogenous synthesis - without
altering n-6 levels [16-18] also result in a significant in-
crease in the n-3/n-6 ratio. In fact, flavonoids are associated
with a decreased BC risk [19,20].
Organic plant foods contain more polyphenols than
similar conventional foods [21-24] and organic animal
fat - for instance milk and milk products [25-27] - does
have a higher n-3/n-6 ratio compared with conventional
products. Thus, women who wish to decrease their BC
risk may select organic plant and animal foods. Regarding
food contaminants, a report from the American Institute
of Medicine states that none of the potentially carcinoge-
netic contaminants, including organochlorine pesticides
and polychlorinated biphenyls (PCBs), is linked to BC risk
[28]. However, recent studies showing strong association
between either estrogenic PCB congeners or dioxin and
BC risk [29-31] do not confirm these optimistic conclu-
sions. While further studies are needed, including studies
of polymorphisms in the cytochrome P450 1A1 (CYP1A1)
gene [32] (likely a confounding factor when studying the
associations between PCBs and BC risk), these data are
not reassuring. Regarding CYP1A1, this member of the
CYP1 family participates in the metabolism of a vast num-
ber of xenobiotics including PCBs and dioxin. Four single
nucleotide polymorphisms in CYP1A1 have been studied
concerning their potential implication on BC. A recent
meta-analysis pointed to the A2455G G allele as a risk fac-
tor for BC among subjects of Caucasian origin [32]. Thus,
further studies analyzing the relationships between estro-
genic PCB congeners and BC risk should include CYP1A1
polymorphisms as a potential marker of genetic predis-
position to BC. In this context it is critical to recall that
endocrine disruptors - such as phthalates - increase insu-
lin resistance, diabetes and obesity [33-35], all of which
increase BC risk (see below).
In the next section, we examine the critical importance
of two major factors in breast cancer risk. One is protect-
ive (the modernized Mediterranean diet) whereas statins
increase risk. The effects of both can be more easily
understood at the light of the factors analyzed in the
“Background” section.
Discussion
Statins and breast cancer risk
Other substances that influence both n-3/n-6 ratio and
BC risk are the cholesterol-lowering statins. The effectof statins on cancer risk is a long story and still today
there is no consensus [36-38]. The controversy began in
1996 with the publication of the Cholesterol and Recur-
rent Events (CARE) trial [39]. It was a double-blind ran-
domized trial comparing the effects (versus placebo) of
the cholesterol-lowering pravastatin against coronary
event after myocardial infarction in 3,583 men and 576
women. Twelve out of 286 women in the statin group
but only one out of 290 in the placebo group had BC at
follow-up [39]. After that, most statin investigators took
care not to include high-risk women in their trials [37]
and carefully monitored them through repeated interim
analyses for early detection of inter-group difference
trends in cancer incidence. To further confuse the data,
many statin trials were prematurely terminated - and it
is likely that not all have been published - without valid
scientific justification. Clearly, cancers diagnosed during
drug trials are unlikely to be ex nihilo cancers and more
likely to be dormant cancers clinically exposed by the
treatment being investigated. As the process requires a
minimal length of exposure, premature termination is
the best way of avoiding the cancer issue in relation to
any investigated drug. However, this process leads to
confusion and prevents clarification of whether the in-
vestigated drug may increase cancer risk in the non-
selected general population in whom the drug is then
prescribed without precaution by unaware physicians.
Despite this, a meta-analysis of clinical trials published
in 2006 found a 33% increase in BC incidence with sta-
tins compared with a placebo [40]. It is noteworthy that
confidence intervals were large (from 0.79 to 2.26) in
that meta-analysis. However, there was great heterogen-
eity between trials (drug dosage, length of exposure) and
curiously only five of the 26 randomized trials reported
BC data [40], suggesting a striking lack of completeness
of reporting of patient-relevant clinical trial outcomes, a
well-known major source of bias and a substantial threat
to the validity of clinical research findings [41]. In view
of the inherent limitations of randomized trials discussed
above, in particular premature termination and short
follow-up, data from observational studies are critical to
examine the statin-BC relationship.
In general, meta-analyses of observational studies re-
ported no association between statin use and BC inci-
dence. However, since high cholesterol may reduce cancer
risk (see below), and as patients taking statins have spent
most of their lives with high cholesterol - which is thought
to lower cancer risk [37] - observational epidemiology is
also facing difficulty in identifying statin cancer signals. In
that context, even a lack of difference in BC risk between
statin users and non-users in observational studies with
long follow-up may suggest that statins increase BC risk.
The recent demonstration that long-term (10-year) statin
use was associated with a two-fold increase in BC risk
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firms the previous data suggesting that statins increase
BC risk [36-40]. Regarding statin prescription and BC
recurrence specifically, a Danish study suggested that
one particular highly lipophilic statin (simvastatin) may
be associated with a reduced risk [43]. However, as
admitted by the authors, their study suffers major
limitations. Briefly, the duration of exposure was short
(a median of four years), the number of recurrences was
small (n = 249 among statin users) and, very important,
statin users and non-users were very different at baseline.
This rendered adjustments for the many confounders -
knowing that factors implicated in recurrence are not ne-
cessarily similar as those implicated in incidence - and
between-group comparison very problematic. Still more
important and admitted by the authors [43], confounding
by indication likely explains their data [44] as the major in-
dication for statin therapy is hypercholesterolemia, which is
inherently associated with lower risk of BC recurrence [45].
The next question is whether there are biological ex-
planations for the effect of statins on BC risk. First, sta-
tins interfere negatively with the metabolism of n-3
and n-6 - that is, they decrease the n-3/n-6 ratio
[46-48] - which may in turn increase BC risk [13,14].
Second, statins lower cholesterol, and low cholesterol
is often (but not always) associated with a high cancer
rate [37]. Inconsistency in the cholesterol-cancer data
is likely to reflect the existence of confounding factors.
One of these factors could be insulin resistance or
metabolic syndrome [49,50]. The Metabolic Syndrome
and Cancer Project (Me-Can) - with more than 577,000
participants and a mean follow-up of 11.7 years - reported
that cholesterol is negatively associated with BC risk, and
this is a critical finding [50]. Third, a substance arising
from cholesterol (dendrogenin A) is a key factor in the
development of human BC [51], reinforcing the theory
that high cholesterol may be protective. Fourth, statins are
toxic to mitochondria [52,53], and mitochondrial dysfunc-
tion contributes to tumorigenesis and cancer progression
[54,55]. Fifth, converging evidence supports the hypothesis
that statins increase insulin resistance and new-onset dia-
betes, possibly (but not only) through mitochondrial tox-
icity in the muscles and other tissues [56-59]. This major
side effect of statins was initially underestimated with
regrettable consequences, some experts even stating
that ‘the cardiovascular benefits of statin therapy ex-
ceed the diabetes hazard’ [60] while the trials upon
which these claims were based were obviously flawed
[61,62]. By contrast, studies indicate highly significant
increases of incident diabetes among statin users [63,64],
culminating in a 70% increase among postmenopausal
women in the Women’s Health Initiative [65]. At the same
time, it was learned that diabetes increases BC risk [66,67]
as well as the overall risk of cancers and cancer death [68].As diabetes is also a marker of long-standing insulin resist-
ance - with chronically high insulin levels and high fasting
blood glucose - it is critical that metabolic syndromes have
also been associated with BC risk [69-72].
Recently, investigators curiously claimed that hyper-
cholesterolemia is a risk factor for BC and that lowering
circulating cholesterol levels (or interfering with its
conversion to 27-hydroxycholesterol) may be a useful
strategy to prevent and/or treat BC [73]. However, the
effects of 27-hydroxycholesterol were tested in rather
artificial cellular and animal models of BC and hyper-
cholesterolemia [73]. Studies using more humanized
models are required before these data could have any
clinical impact. Finally, statins have been shown to in-
crease the number of immune regulatory T cells, which
in turn may hinder antitumor defenses and increase
cancer risk [74].
Thus, statins may increase BC risk through increased
insulin resistance and new-onset diabetes, decreased
n-3/n-6 ratio, cholesterol lowering, mitochondrial toxicity
and an immunomodulatory effect. Statin use also re-
sults in skeletal muscle toxicity and decreased physical
activity [56-58]. For decreasing BC risk, reducing insu-
lin resistance, metabolic syndromes and diabetes risk is
beneficial, as shown with the Mediterranean diet in the
next section. Additionally, international guidelines [1-3]
recommend that women aim for optimal physical activity,
which is known to decrease risk for both diabetes [75,76]
and BC [1-4]. They also recommend that women should
limit weight gain, especially around menopause, to reduce
BC risk [1-3]. In that context, a recent report - 27,886
adults, 10-year follow-up - of a rapid increase in body
mass index (equivalent to a 3- to 5-kg weight gain) among
statin users compared with non-users is of concern [77].
Whatever the causes of that weight gain, be it reduced
physical activity in relation with skeletal muscle toxicity
[56-58], increased insulin resistance or increased caloric in-
take [77], it may contribute to the statin-induced increase
in BC risk.
Regarding diabetes risk, increased fiber intake and
consumption of flavonoids and n-3 are all inversely as-
sociated with diabetes risk [78-82]. In line with the fact
that diabetes increases BC risk, not surprisingly fiber
intake [83-86], flavonoids [19,20] and n-3 [8,10,13,14]
are inversely associated with BC risk.
Finally, consumption of foods with a low glycemic
impact - that is, foods with a low glycemic index (GI) - is as-
sociated with lower risks of diabetes [87,88] and BC [89-92].
Modernized Mediterranean diet and breast cancer risk
The Mediterranean diet, the traditional dietary habits
of people living around the Mediterranean Sea, is a
well-known healthy dietary pattern [93]. A modernized
version that includes traditional Mediterranean foods
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and foods not traditionally available to Mediterranean
populations (for example, canola oil, margarines, low-fat
dairy products) was tested in randomized trials and resulted
in health benefits [93,94]. The combination of high fiber,
high n-3/n-6 ratio, high polyphenols and low-GI foods
represents a healthy dietary pattern. Adoption of such
a healthy diet is clearly associated with a lower BC risk
[95-99]. Among women with early-stage BC, increased
adherence to a similar healthy dietary pattern was as-
sociated with decreasing risk of overall death and death
from non-BC causes (p = 0.003) [100]. There was also a
trend toward less BC death, the lack of statistical sig-
nificance being explained by the quite small (n = 1,900)
sample size and small number of BC deaths (n = 128)
[100]. More specifically, increased adherence to the
Mediterranean diet pattern is also clearly associated with
fewer cancers [101], specifically pancreatic [102], gastric
[103], colorectal [104], hepatocellular [105], prostate [106]
and breast [107-109]. This is not unexpected since the
Mediterranean diet increases the n-3/n-6 ratio on the
one hand [10,93] and on the other decreases the risk of
metabolic syndrome [110,111] and diabetes [112,113],
both of which increase the risk of cancer - including
BC - and cancer deaths [66-72]. Also, phenolic compo-
nents of olive oil lowered body iron stores, which in
turn may lower insulin resistance and metabolic syndrome
[114]. Finally, the Mediterranean diet is an effective
strategy for obtaining statistically and clinically signifi-
cant weight loss [115-117], which in turn is considered
a valuable strategy to reduce BC risk and improve survival
after diagnosis [1-4].
The only limitation regarding the prevention of BC
through adherence to the Mediterranean diet regards
alcohol consumption. Moderate wine drinking is indeed
a component of the traditional Mediterranean diet [93].
However, alcohol consumption increases BC risk [118],
while the specific effect of wine is still unclear. The usual
estimate for postmenopausal women who consume no
more than one alcoholic drink per day is a 7% to 10%
risk increase in comparison with non-drinkers [1,2].
This is small but significant. Alcohol consumption may
also increase BC recurrence [119]. Women who use
postmenopausal hormones should take particular care
with BC risk in relation to alcohol consumption [1-4].
In some [120,121] but not all [122] studies, the excess BC
risk with alcohol consumption is reduced by increasing
the intake of folate. Accordingly, experts have stated that
the Mediterranean way of drinking alcohol - regular and
moderate consumption of polyphenol-rich wine mainly
with folate-rich foods - does not appreciably influence the
overall risk of cancer [123]. Given that moderate alcohol
consumption also reduces the risk of cardiovascular
disease [124], it appears that consuming approximatelyone alcoholic drink per day on average, including after BC
diagnosis, is associated with optimal life expectancy without
compromising BC-specific survival [125-127].Summary
Adhering to a healthy dietary pattern, specifically the
modernized Mediterranean diet [93,94], should be the
cornerstone of a lifestyle strategy to reduce BC risk in
high-risk women and in women who wish to decrease
their BC risk.
In the context of the Mediterranean diet, it is critical
to increase plant and marine n-3 and decrease plant and
animal n-6. High flavonoid consumption - which increases
marine n-3 [16-18] - should be encouraged as it is associ-
ated with lower BC risk. To reduce insulin resistance and
diabetes, which are associated with an increased BC risk,
we argue that women should increase their consumption
of fiber and favor low-GI foods. As far as possible, we feel
that women should choose organic foods because of their
effect on the n-3/n-6 ratio and because they contain fewer
contaminants - and lower levels of each contaminant - in
particular endocrine disruptor. Finally, we strongly argue
that any drug thought to increase diabetes and/or BC
risk - in particular, the statins and certain antihypertensive
medications [128,129] - should be considered with a great
deal of precaution and even prohibited in high-risk
women. To lower blood pressure or to decrease the risk
of cardiovascular disease, physicians do have alternative
drugs and lifestyle strategies and it would be tragically
unwise to persist in prescribing these specific anticho-
lesterol and antihypertensive drugs in women wishing
to decrease their BC risk.
National and international guidelines recommend healthy
diet and physical activity to decrease BC risk [130]. We
agree with this advice. It is time, however, to go further
and be more specific. A specific dietary pattern such as
the modernized Mediterranean diet, and not simply
‘consuming a diet rich in vegetables and fruits’, should
be adopted to decrease BC risk. This is also an effective
way of maintaining a healthy weight and preventing
diabetes and cardiovascular disease. This also applies
to BC survivors to prevent recurrence and improve
survival [131,132].
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